通过与HDAC抑制剂的结合,提高venetoclax在白血病中的疗效
Jorge Antonio Elias Godoy Carlos1, Mauricio Temotheo Tavares2,3,4, Keli Lima1,5
1Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Cell death discovery
|April 5, 2025
概括
新型混合激酶/胰岛素脱乙酶 (HDAC) 抑制剂,如化合物4f,在治疗急性髓性白血病 (AML) 中表现有前途. 这些化合物降低癌细胞活力,增强venetoclax的疗效,为耐药性血液癌症提供希望.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 表观遗传修饰调节基因表达,并与癌症发展有关.
- 基斯脱乙酶 (HDAC) 抑制剂正在成为血液性恶性瘤的治疗策略.
研究的目的:
- 研究新型 purin-benzohydroxamate 化合物,特别是 4f,作为混合激酶/HDAC 抑制剂在血液恶性瘤中的疗效,重点是急性髓性白血病 (AML).
- 评估单独和与venetoclax结合的4f的潜力,以克服AML的耐药性.
主要方法:
- 新型 purin-benzohydroxamate 化合物的合成和表征.
- 在实验室中评估白血病细胞系和正常白血细胞中的细胞活力,细胞亡和细胞循环停止.
- 酶抑制测试以确定HDAC抑制活性.
- 在敏感和耐药AML模型中与venetoclax进行组合研究.
主要成果:
- 化合物4f选择性地比正常白细胞更有效地降低了血液癌细胞的活力.
- 4f诱导了细胞亡,细胞循环停止和白血病细胞的分化,同时抑制了HDAC活性.
- 4f与venetoclax的组合表明了协同作用,显著增加了AML模型中的细胞亡和减少细胞活力,包括那些对venetoclax耐药的模型.
结论:
- 新型混合激酶/HDAC抑制剂,以4f为例,代表了血液性恶性瘤的有前途的治疗途径,特别是耐药的AML.
- 涉及HDAC抑制剂的组合疗法,如4f,可以克服耐药性并改善急性白血病和其他血液癌症患者的结果.
- 对混合激酶/HDAC抑制剂的进一步研究是有必要的,以便在瘤学中开发先进的治疗策略.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:10Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K